# US 2013/0296354 A1 · 2,3-DIHYDROFURO[2,3-c]PYRIDINES, THEIR USE AS MODULATORS OF THE G-PROTEIN-COUPLED RECEPTOR GPR119 AND PHARMACEUTICAL COMPOSITIONS THEREOF

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0296354 A1
- Document ID: US20130296354A1
- Status: Published application
- Kind: A1
- Application number: 13/887,887
- Filed: 2013-05-06
- Published: 2013-11-07
- Earliest claimed: 2012-05-07
- Assignees: Boehringer Ingelheim International GmbH
- Inventors: Matthias ECKHARDT
- Web page: https://patentgrep.com/patent/US20130296354A1

## CPC

- C07D 491/20: Spiro-condensed systems
- A61K 31/438: The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compounds of general formula I, wherein the groups R1 and A are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.

## Claims

### Claim 1

A compound of formula I
wherein:
R1 is selected from the group R1-G1 consisting of: (a) a 5- or 6-membered heteroaromatic ring containing 1, 2, or 3 heteroatoms independently of selected from N, O, and S, optionally substituted with a group RC and/or one or more substituents independently selected from LA, (b) a group C(═O)—O—Ra, wherein Ra is C1-6-alkyl optionally mono- or polysubstituted with fluorine, or C3-6-cycloalkyl optionally mono- or polysubstituted with fluorine and optionally substituted with a group selected from CH3, CF3, and CHF2; and (c) a group CH2—Rb, wherein Rb is C1-6-alkyl optionally mono- or polysubstituted with fluorine, or C3-6-cycloalkyl optionally mono- or polysubstituted with fluorine and optionally substituted with a group selected from CH3, CF3, and CHF2;
A is selected from the group A-G1 consisting of: (a) piperidin-4-yl, 1,2,3,6-tetrahydropyridin-4-yl, 5-methyl-1,2,3,6-tetrahydro-pyridin-4-yl, and piperazin-1-yl, each substituted at the N with a C1-4-alkyl-S(═O)2— group; and (b) a phenyl ring and a 6-membered heteroaromatic ring containing 1 or 2 N, each optionally substituted with a group T and optionally substituted with one or more substituents independently selected from LA;
T is selected from the group T-G1 consisting of F, Cl, Br, I, CN, OH, NO2, C1-6-alkyl-, C1-6-alkenyl-, C1-6-alkynyl-, C3-6-cycloalkyl, C1-6-alkyl-O—, C3-6-cycloalkyl-O—, C1-6-alkyl-S—, HO—C(═O)—, C1-6-alkyl-O—C(═O)—, C3-6-cycloalkyl-C(═O)—, C1-4-alkyl-S(═O)—, C1-4-alkyl-S(═O)2—, RNT1RNT2N—, RNT1RNT2N—C(═O)—, RNT1RNT2N—S(═O)2—, RNT1RNT2N—C(═O)—(RN)N—, heterocyclyl, heterocyclyl-O—, aryl, aryl-O—, heteroaryl and heteroaryl-O—, wherein each alkyl, alkenyl, alkynyl, and cycloalkyl group is optionally substituted with one or more substituents independently selected from F, Cl, CN, OH, C1-3-alkyl, C3-6-cycloalkyl, C1-3-alkyl-O—, RNT1RNT2N—, RNT1RNT2N—C(═O)—, C1-4-alkyl-S(═O)—, C1-4-alkyl-S(═O)2—, RNT1RNT2N—S(═O)2—, aryl, aryl, heteroaryl, and heterocyclyl, and
wherein heteroaryl is a 5- or 6-membered aromatic ring which contains 1, 2, 3, or 4 heteroatoms independently selected from N, O, and S, wherein the H-atom in one or more NH groups are optionally replaced by RN; and
wherein heterocyclyl is a 4- to 7-membered unsaturated or saturated carbocyclic ring in which 1, 2, or 3 —CH2-groups are independently replaced by NRN, O, —C(═O)—, S, —S(═O)—, or —S(═O)2—, and/or in which a —CH<group is replaced by N;
RN is independently is selected from the group RN-G1 consisting of H, C1-4-alkyl, C1-4-alkyl-C(═O)—, and C1-4-alkyl-S(═O)2—;
RNT1 is selected from the group RNT1-G1 consisting of H, C1-6-alkyl, C3-6-cycloalkyl, C1-6-alkyl-C(═O)—, C1-6-alkyl-S(═O)2, heterocyclyl, aryl. and heteroaryl,
wherein each alkyl and cycloalkyl group is optionally substituted with one or more substituents independently selected from the group consisting of F, OH, CN, C1-4-alkyl, C1-4-alkyl-O—, RN2N, C1-4-alkyl-S(═O)2—, C3-6-cycloalkyl, heterocyclyl, phenyl, and heteroaryl; and
wherein heterocyclyl is optionally substituted with one or more substituents independently selected from F, C1-4-alkyl, RN2N, OH, and C1-4-alkyl-O—; and
wherein heterocyclyl is a C4-7-cycloalkyl ring in which 1 or 2 —CH2-groups are independently replaced by NRN, O, C(═O), S, S(═O) or S(═O)2; and
wherein heteroaryl is a 5- or 6-membered aromatic ring which contains 1, 2, or 3 heteroatoms independently selected from N, O, and S, wherein the H-atom in one or more NH groups is optionally replaced by RN; and
RNT2 is selected from the group RNT2-G1 consisting of H and C1-6-alkyl; or
RNT1 and RNT2 are linked to form one group selected from the group RNT1RNT2-G1 consisting of a C3-5-alkylene group, wherein 1 or 2 —CH2-groups are independently replaced by NRN, O, C(═O), S, S(═O), or S(═O)2; and are optionally substituted with one or more substituents independently selected from F, C1-4-alkyl, (RN)2N, OH, and C1-4-alkyl-O—;
LA is selected from the group LA-G1 consisting of F, Cl, Br, CN, OH, NO2, C1-4-alkyl-, C1-4-alkyl-O—, (RN)2N—C(═O), (RN)2N—, and C1-4-alkyl-S(═O)2—, wherein each alkyl group is optionally substituted with one or more substituents independently selected from F, Cl, CN, OH, and C1-3-alkyl-O—; and
RC is selected from the group RC-G1 consisting of F, Cl, Br, I, CN, OH, NO2, C1-6-alkyl-, C2-6-alkenyl-, C2-6-alkynyl-, C3-6-cycloalkyl, C1-6-alkyl-O—, C3-6-cycloalkyl-O—, C1-6-alkyl-S—, HO—C(═O)—, C1-6-alkyl-O—C(═O)—, C1-4-alkyl-C(═O)—, C3-6-cycloalkyl-C(═O)—, C1-4-alkyl-S(═O)—, C1-4-alkyl-S(═O)2—, RNT1RNT2N—, RNT1RNT2N—C(═O)—, RNT1RNT2N—S(═O)2—, RNT1RNT2N—C(═O)—(RN)N—, heterocyclyl, heterocyclyl-O—, aryl, aryl-O—, heteroaryl, and heteroaryl-O—, wherein each alkyl, alkenyl, alkynyl, and cycloalkyl group is optionally substituted with one or more substituents independently selected from F, Cl, CN, OH, C1-3-alkyl, C3-6-cycloalkyl, C1-3-alkyl-O—, RNT1RNT2N—, RNT1RNT2N—C(═O)—, C1-4-alkyl-S(═O)—, C1-4-alkyl-S(═O)2—, RNT1RNT2N—S(═O)2—, aryl, heteroaryl, and heterocyclyl,
wherein heteroaryl is a 5- or 6-membered aromatic ring which contains 1, 2, 3, or 4 heteroatoms independently of each other selected from N, O and S, wherein the H-atom in one or more NH groups may be optionally replaced by RN; and
wherein heterocyclyl is a 4- to 7-membered unsaturated or saturated carbocyclic ring in which 1, 2 or 3 —CH2-groups independently of each other are replaced by NRN, O, —C(═O)—, S, —S(═O)— or —S(═O)2—, and/or in which a —CH-group is replaced by N; and
wherein:
aryl is phenyl or naphthyl, and
each aryl, heteroaryl, or heterocyclyl group is optionally substituted with one or more substituents independently selected from LA,
or a salt thereof.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein R1 is selected from a group consisting of:
wherein each ring is optionally substituted with one substituent RC;
wherein each alkyl residue is substituted with 1 to 3 F atoms; and

### Claim 3 (depends on 1)

The compound according to claim 1, wherein A is selected from a group consisting of:
each optionally additionally substituted with one CN group or with one or two F atoms; and

### Claim 4 (depends on 1)

The compound according to claim 1, wherein T is selected from a group consisting of —CN, C1-4-alkyl-S—, C1-4-alkyl-S(═O)2—CH2—, C1-4-alkyl-S(═O)2, RNT1RNT2N—S(═O)2—, RNT1RNT2N—C(═O)—, C1-4-alkyl-S(═O)2—(RN)N—, and RNT1RNT2N —.

### Claim 5 (depends on 1)

The compound according to claim 1, wherein RC is selected from a group consisting of F, Cl, Br, CN, C1-4-alkyl-, C3-6-cycloalkyl, C1-4-alkyl-O—, C3-6-cycloalkyl-O—, heterocyclyl, and heterocyclyl-O—,
wherein each alkyl and cycloalkyl group is optionally substituted with one or more fluorine atoms and a substituent selected from H3C— and H3C—O—, and
wherein heterocyclyl is selected from the group consisting of oxetanyl, tetrahydrofuranyl, and tetrahydropyranyl, each optionally substituted with one or two H3C— groups.

### Claim 6 (depends on 1)

The compound according to claim 1, wherein:
R1 is selected from the group consisting of:
wherein each ring is optionally substituted with one substituent RC;
wherein each alkyl residue may be substituted with 1 to 3 F atoms; and
RC is selected from the group consisting of Cl, C1-3-alkyl, cyclopropyl, F3C—, and isopropyl-O—;
A is selected from the group consisting of:
each of which may be additionally substituted with one CN group or with one or two F atoms; and
and
T is selected from the group consisting of NC—, CH3—S—, CH3—CH2—NH—C(═O)—, CH3—S(═O)2—CH2—, and CH3—S(═O)2—;
and the pharmaceutically acceptable salts thereof.

### Claim 7 (depends on 1)

The compound according to claim 1, wherein:
R1 is selected from the group consisting of
and
A is selected from the group consisting of
and the pharmaceutically acceptable salts thereof.

### Claim 8 (depends on 1)

The pharmaceutically acceptable salt of a compound according to claim 1.

### Claim 9 (depends on 1)

A pharmaceutical composition comprising the compound according to claim 1 or a pharmaceutically acceptable salt thereof, and an inert carrier or diluent.

### Claim 10 (depends on 1)

A method for treating diseases or conditions which are mediated by activating the G-protein-coupled receptor GPR119, comprising administering to a patient in need thereof the compound according to of claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 11

(canceled)

### Claim 12 (depends on 10)

The method according to of claim 10 wherein the diseases or conditions which are mediated by activating the G-protein-coupled receptor GPR119 is diabetes, obesity, or dyslipidemia.

### Claim 13

(canceled)
